Jubilant Ingrevia Limited — Updates, 13-05-2025: Press Release

Jubilant Ingrevia has announced a board meeting on the financial results for the quarter and half-year. Specialty Chemicals and Nutrition segments led growth, with EBITDA margin rising to 14.7% and profit after tax surging 153% YoY. Specialty Chemicals benefited from stable volumes and price gains in Pyridine derivatives, while Nutrition showed strong volume growth in Choline and Niacinamide. Chemical Intermediates faced volume and pricing pressures. Capex of ₹65 Cr supports expansions in fine chemicals, CDMO, and nutrition. Net working capital efficiency also improved.